A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Hoffmann-La Roche
Incyte Corporation
Novartis
OHSU Knight Cancer Institute
Hoag Memorial Hospital Presbyterian